Blue Bell Private Wealth Management’s Arbutus Biopharma ABUS Stock Holding History

Blue Bell Private Wealth Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-500	Closed	-$1.25K	–	723
2023 Q4	$1.25K	Hold	500	–	–	﹤0.01%	658
2023 Q3	$1.01K	Sell	500 -1,000	-67%	-$2.1K	﹤0.01%	631
2023 Q2	$3.45K	Hold	1,500	–	–	﹤0.01%	538
2023 Q1	$4.54K	Hold	1,500	–	–	﹤0.01%	475
2022 Q4	$3.5K	Hold	1,500	–	–	﹤0.01%	515
2022 Q3	$3K	Hold	1,500	–	–	﹤0.01%	535
2022 Q2	$4K	Hold	1,500	–	–	﹤0.01%	531
2022 Q1	$4K	Hold	1,500	–	–	﹤0.01%	576
2021 Q4	$6K	Buy	+1,500	New	+$5.83K	﹤0.01%	484

Other funds holding ABUS

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return